RxDoctor Payments Data

James Cardi, MD

Internal Medicine · Cranston, RINPI 1104890292

Payments from drug & device makers

$3,503in general payments, 2019–2025

Across 165 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$706
  • AbbVie$347
  • Johnson & Johnson$322
  • Boehringer Ingelheim$310
  • AstraZeneca$285
  • Teva Pharmaceuticals USA, Inc.$271
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,64375%
  • Education$1003%
  • Gifts$542%
  • Other$70620%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,503 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$75,977
Medicare patients
178
Services billed
799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$70,135
JardianceEmpagliflozin85$69,016
EliquisApixaban78$51,472
XareltoRivaroxaban30$23,129
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl79$18,575
Breo ElliptaFluticasone/Vilanterol37$14,600
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,847
SuboxoneBuprenorphine Hcl/Naloxone Hcl17$11,818
JanuviaSitagliptin Phosphate14$8,113
Diclofenac Sodium13$7,438
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,391
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$5,087
Atorvastatin Calcium395$4,344
SymbicortBudesonide/Formoterol Fumarate17$3,995
Buprenorphine Hcl38$3,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$70,13575 claims
Boehringer IngelheimJardiance$310$69,01685 claims
PfizerEliquis$164$51,47278 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$190$34,83872 claims
Johnson & JohnsonXarelto$322$23,12930 claims
Indivior Inc.Suboxone$177$11,81817 claims
AstraZenecaSymbicort$285$3,99517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →